Clinical Trials Below are current clinical trials.75 studies in Pulmonary, Critical Care, and Sleep Medicine (open studies only). Filter this list of studies by location, status and more. The Relationship Between Critical Care Physicians' Characteristics and Their Clinical Practice Patterns Rochester, Minn. The purpose of this study is to identify the magnitude of variation among intensivists in use of diagnostic testing and to determine whether variation in diagnostic test ordering patterns among intensivists attributables to their personal characteristics, or to factors in the clinical environment. Donor-Specific Cell Free DNA Monitoring of Thoracic Allografts Rochester, Minn., Jacksonville, Fla. The purpose of this study is to determine if DNA originating from the transplanted heart or lung can be detected in the blood and used to monitor for rejection. Study of the Incidence of Electrographic Status Epilepticus and Seizures of PICU Patients at National Children’s Hospital in Hanoi, Vietnam. Rochester, Minn. The purpose of the study is: To determine the incidence of subclinical electrographic seizures and electrographic status epilepticus in children admitted to the PICU for head trauma, traumatic brain injury (TBI), and/or child abuse at National Children’s Hospital in Hanoi, Vietnam. To determine whether a correlation exists between length of stay, morbidity, and mortality with incidence of subclinical SE and seizures. A Study of Performing Surgery for Resectable Malignant Pleural Mesothelioma After Radiation Therapy Rochester, Minn. The purpose of this study is to assess the possibility, safety, and therapeutic effect of administering a short, quick course of high-dose radiation treatment focused on half of the chest, followed by surgery to remove that portion of the lungs, in patients with malignant pleural mesothelioma. A Study to Evaluate Lamprene (Clofazimine) to Treat Non-Tuberculous Mycobacterial (NTM) Infections Jacksonville, Fla. The purpose of this study is to evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections. A Study to Evaluate Exercise Capacity and Positive Airway Pressure Impact on Sleep Apnea in Heart Failure Rochester, Minn. The purpose of this study is to determine the prevalence of Obstructive Sleep Apnea (OSA) in HFpEF, and its clinical and hemodynamic correlates, and to determine the impact of intervention with CPAP therapy on exercise capacity and quality of life in HFpEF patients with OSA. A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety and tolerability of ixazomib in patients with scleroderma. A Study to Collect Thoracic Specimens to Develop a Thoracic Specimen Registry Rochester, Minn., Scottsdale/Phoenix, Ariz. The primary objective of this proposal is to develop a Thoracic Specimen Registry at Mayo Clinic. The purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases. SBRT with Immunotherapy for Mesothelioma Rochester, Minn. The purpose of this study is to evaluate whether adding stereotactic body radiation therapy (SBRT) to immunotherapy as part of second line treatment for mesothelioma will improve the modest response rate of immunotherapy alone, provide local control/cytoreduction to sites of gross disease, and decrease symptomatic burden while improving outcomes. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of SAR444881 alone and in combination with pembrolizumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy and will be comprised of two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) and 1C (SAR444881 in combination with cetuximab) followed by a dose optimization/expansion phase (Part 2), including Sub-Part 2A (Dose Optimization) with Cohorts A1 (SAR444881 in combination with pembrolizumab, carboplatin, and pemetrexed), A2 (SAR444881 in combination with pembrolizumab), B1 (SAR444881 in combination with pembrolizumab and later therapy), and C1 (SAR444881 in combination with cetuximab and later therapy), as well as Sub-Part 2B (Dose Expansion) with Cohort D1 (monotherapy SAR444881). Pagination Clinical studies PrevPrevious Page Go to page 11 Go to page 22 Go to page 33 Go to page 44 Go to page 55 NextNext Page Medical Professionals Pulmonary, Critical Care, & Sleep Medicine Clinical Trials